Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Leukemia & Lymphoma|December 29, 2012
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemiaEllen K Ritchie, Eric J Feldman, Paul J Christos, et al.
Leukemia & Lymphoma|May 3, 2008
Feasibility of administering oblimersen (G3139; Genasense) with imatinib mesylate in patients with imatinib resistant chronic myeloid leukemia--Cancer and leukemia group B study 10107Meir Wetzler, Kathleen A Donohue, Olatoyosi M Odenike, et al.
Leukemia Research|October 20, 2010
Arsenic trioxide and low-dose cytarabine for patients with intermediate-2 and high-risk myelodysplastic syndromeGail J Roboz, Ellen K Ritchie, Tania Curcio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2014
Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxideGail J Roboz, Ellen K Ritchie, Rebecca F Carlin, et al.
Leukemia & Lymphoma|May 6, 2014
Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndromeGail J Roboz, H Jean Khoury, Elias Jabbour, et al.
Cancer|October 1, 2008
Arsenic trioxide and low-dose cytarabine in older patients with untreated acute myeloid leukemia, excluding acute promyelocytic leukemiaGail J Roboz, Ellen K Ritchie, Tania Curcio, et al.
Leukemia & Lymphoma|June 27, 2009
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trialAzra Raza, Joseph G Jurcic, Gail J Roboz, et al.
Leukemia Research|June 15, 2007
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasiaFrancis J Giles, Alan F List, Michael Carroll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 2, 2011
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemiaEric J Feldman, Jeffrey E Lancet, Jonathan E Kolitz, et al.
Blood|September 20, 2021
Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemiaDaniel J DeAngelo, Brian A Jonas, Jane L Liesveld, et al.
Pageof 5